Trigone Pharma Ltd.
🇮🇱Israel
Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
Phase 2
Recruiting
- Conditions
- Non Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Trigone Pharma Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06663137
- Locations
- 🇮🇱
Avi Gordon, Raanana, Israel
© Copyright 2025. All Rights Reserved by MedPath